drugset / Trial / NCT07645248

A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

NCT07645248 ↗

Phase 3 Not yet recruiting 110 enrolled GlaxoSmithKline
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).

Timeline

Start
2026-09-15
Primary completion
2027-02-25
Completion
2027-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject HFA-152A Unknown — Inhaled
Subject NORFLURANE Other / unclassified — Inhaled

Indications